Meclofenamic acid sodium
Based on 9 publication(s) in Google Scholar
Meclofenamic acid (Meclofenamate) sodium is a non-steroidal anti-inflammatory agent (NSAID). Meclofenamic acid sodium is a non-selective gap-junction blocker and a highly selective inhibitor of fat - and obesity-related enzyme (FTO). Meclofenamic acid sodium has anti-inflammatory and antitumor activities.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.89%
- No. CAS: 6385-02-0
- Fòrmula: C14H10Cl2NNaO2
- Peso molecular:318.13
-
Almacenamiento:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-15036
DiclofenacCOX Inhibitor -
HY-14397
IndomethacinCOX1/2 Inhibitor -
HY-B0335
Tolfenamic AcidCOX-2 Inhibitor -
HY-78131
IbuprofenCOX-1 Inhibitor -
HY-P0139
Gap 27Gap Junction Inhibitor -
HY-50202
EtomoxirCPT1a Inhibitor -
HY-N0180
18β-Glycyrrhetinic acidEndogenous Metabolite -
HY-B0006
Carvedilolβ/α-1 Blocker -
HY-15027
5-Aminosalicylic AcidEndogenous Metabolite -
HY-B0218
OrlistatFASN Inhibitor -
HY-B0574
Mefenamic acidCOX Inhibitor -
HY-127103
FB23-2FTO Inhibitor
Publications Citing Use of MedChemExpress (MCE) Meclofenamic acid sodium
More- Cancer Commun (Lond). 2025 May;45(5):608-631. [Abstract]
- Theranostics. 2021 Jul 25;11(17):8464-8479. [Abstract]
- Sensor Actuat B-Chem. 2021, 129983.
- Biomater Adv. 2023 Nov:154:213634. [Abstract]
- Biochem Pharmacol. 2026 Apr:246:117710. [Abstract]
- PLoS Pathog. 2025 Jan 21;21(1):e1012895. [Abstract]
- Biomed Opt Express. 2021 Mar 9;12(4):1962-1973. [Abstract]
- Res Sq. 2026 Apr 6.
- SSRN. 2025 Jan 27.
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
Actividad biológica
Descripciòn
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RBL-1 | IC50 |
0.1 μM
Compound: 4
|
Inhibition of Prostaglandin G/H synthase in intact RBL-1 cell line
Inhibition of Prostaglandin G/H synthase in intact RBL-1 cell line
|
[PMID: 2115586] |
| RBL-1 | IC50 |
0.1 μM
Compound: sodium meclofenamate
|
Inhibition of prostaglandin G/H synthase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187
Inhibition of prostaglandin G/H synthase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187
|
[PMID: 8295221] |
| RBL-1 | IC50 |
0.1 μM
Compound: Sodium Meclofenamate
|
Compound was tested for its inhibitory activity against PGF-2 alpha (CO) formation in RBL-1 cells stimulated with the calcium ionophore A-23187
Compound was tested for its inhibitory activity against PGF-2 alpha (CO) formation in RBL-1 cells stimulated with the calcium ionophore A-23187
|
10.1016/S0960-894X(00)80051-7 |
| RBL-1 | IC50 |
24 μM
Compound: 4
|
Inhibition of 5-lipoxygenase in intact RBL-1 cell line
Inhibition of 5-lipoxygenase in intact RBL-1 cell line
|
[PMID: 2115586] |
| RBL-1 | IC50 |
24 μM
Compound: sodium meclofenamate
|
Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187
Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187
|
[PMID: 8295221] |
| RBL-1 | IC50 |
24 μM
Compound: Sodium Meclofenamate
|
Compound was tested for its inhibitory activity against LTB4 (5-LO) formation in RBL-1 cells stimulated with the calcium ionophore A-23187
Compound was tested for its inhibitory activity against LTB4 (5-LO) formation in RBL-1 cells stimulated with the calcium ionophore A-23187
|
10.1016/S0960-894X(00)80051-7 |
In Vitro
Meclofenamic acid sodium (10, 100, 200 mM, 4 days) inhibits the proliferation and migration of haSMCs[1].
Meclofenamic acid sodium (4, 6 μM, 48 h) combines with gefitinib-induced caspase-related apoptosis of resistant NSCLC cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Prostate tumor model in mice[2]
-
Dosage:10 mg/kg
-
Administration:i.p.
-
Result:Decreased tumor aggression, increased fibrosis, cellular proliferation and vascularity reduction.
Chemical Information
-
No. CAS 6385-02-0
-
Appearance Solid
-
Peso molecular 318.13
-
Fòrmula C14H10Cl2NNaO2
-
Color White to off-white
-
SMILES
O=C(O[Na])C1=CC=CC=C1NC2=C(Cl)C=CC(C)=C2Cl
-
Synonyms
Meclofenamate sodium
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Cancer Commun (Lond)
Helicobacter pylori CagA elevates FTO to induce gastric cancer progression via a "hit-and-run" paradigm. [Abstract]2025 May;45(5):608-631. PMID: 39960839
Meclofenamic acid sodium purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 May;45(5):608-631. [Abstract]
Meclofenamic acid sodium (MA; 50 mg/kg; once every 3 days for 30 days) effectively abolished the contribution of CagA on cell metastasis in the lungs.
Meclofenamic acid sodium purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 May;45(5):608-631. [Abstract]
Meclofenamic acid sodium (MA; 50 mg/kg; once every 3 days for 30 days) effectively abolished the contribution of CagA on cell metastasis in the lungs.
-
Theranostics
2021 Jul 25;11(17):8464-8479. PMID: 34373753
Meclofenamic acid sodium purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 Jul 25;11(17):8464-8479. [Abstract]
The effect of FTO inhibitor Meclofenamate sodium (MS) (80 μM and 120 μM) on ATF4 protein expression and mTORC1 activity during 968 treatment is detected by western blotting. MS efficiently reduces ATF4 expression and rescues the mTOR downregulation induced by compound 968.
Meclofenamic acid sodium purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 Jul 25;11(17):8464-8479. [Abstract]
Meclofenamic acid sodium (MS; 80, 120 μM) efficiently reduced ATF4 expression in HCT116 cells.
-
-
Biomater Adv
Anti-resorption role of low-intensity pulsed ultrasound (LIPUS) during large-scale bone reconstruction using porous titanium alloy scaffolds through inhibiting osteoclast differentiation. [Abstract]2023 Nov:154:213634. PMID: 37783002
Meclofenamic acid sodium purchased from MedChemExpress. Usage Cited in: Biomater Adv. 2023 Nov:154:213634. [Abstract]
Meclofenamic acid sodium (MA; 60 mM) increased the protein expression of CTSK, TRAF6, MMP9, NFATC1 during osteoclast induction in raw264.7 cells.
-
Biochem Pharmacol
Inhibition of Ca2+-activated chloride channels by the NSAID meclofenamate for anti-diarrhea. [Abstract]2026 Apr:246:117710. PMID: 41544862
Meclofenamic acid sodium purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2026 Apr:246:117710. [Abstract]
Meclofenamic acid sodium (meclofenamate; Mec; 5, 20 mg/kg; p.o.; daily for 7 days) significantly alleviated DSS-induced watery stool.
Meclofenamic acid sodium purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2026 Apr:246:117710. [Abstract]
Meclofenamic acid sodium (meclofenamate; Mec; 5, 20 mg/kg; p.o.; daily for 7 days) significantly alleviated the colon shortening induced by DSS with a length of 5.8 ± 0.4 cm for 5 mg/kg and 5.8 ± 1.0 cm for 20 mg/kg.
Meclofenamic acid sodium purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2026 Apr:246:117710. [Abstract]
Meclofenamic acid sodium (meclofenamate; Mec; 5, 20 mg/kg; p.o.; daily for 7 days) significantly alleviated the pathology of colon inflammation induced by DSS, exhibiting mild necrosis of colonic mucosal epithelium, complete structure of glands, and reduced inflammatory cell infiltration.
-
PLoS Pathog
Pseudorabies virus infection triggers pUL46-mediated phosphorylation of connexin-43 and closure of gap junctions to promote intercellular virus spread. [Abstract]2025 Jan 21;21(1):e1012895. PMID: 39836710 -
Biomed Opt Express
Investigating tunneling nanotubes in ovarian cancer based on two-photon excitation FLIM-FRET. [Abstract]2021 Mar 9;12(4):1962-1973. PMID: 33996210 -
-
Solvente y solubilidad
In Vitro:
H2O : 100 mg/mL (314.34 mM; Need ultrasonic)
DMSO : 100 mg/mL (314.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.54 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.54 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocolo
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Pureza y Documentación
-
Ficha de datos (308 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Schober W, et al. Meclofenamic acid for inhibition of human vascular smooth muscle cell proliferation and migration: an in vitro study. Cardiovasc Intervent Radiol. 2002 Jan-Feb;25(1):57-63. [Content Brief]
[2]. Chen H, et al. Meclofenamic Acid Restores Gefinitib Sensitivity by Downregulating Breast Cancer Resistance Protein and Multidrug Resistance Protein 7 via FTO/m6A-Demethylation/c-Myc in Non-Small Cell Lung Cancer. Front Oncol. 2022 Apr 21;12:870636. [Content Brief]
[3]. Schrier DJ, et al. The topical anti-inflammatory effects of a topical preparation of meclofenamic acid on carrageenan-induced footpad swelling in mice. J Pharm Pharmacol. 1987 Jan;39(1):57-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.1434 mL | 15.7168 mL | 31.4337 mL | 78.5842 mL |
| 5 mM | 0.6287 mL | 3.1434 mL | 6.2867 mL | 15.7168 mL | |
| 10 mM | 0.3143 mL | 1.5717 mL | 3.1434 mL | 7.8584 mL | |
| 15 mM | 0.2096 mL | 1.0478 mL | 2.0956 mL | 5.2389 mL | |
| 20 mM | 0.1572 mL | 0.7858 mL | 1.5717 mL | 3.9292 mL | |
| 25 mM | 0.1257 mL | 0.6287 mL | 1.2573 mL | 3.1434 mL | |
| 30 mM | 0.1048 mL | 0.5239 mL | 1.0478 mL | 2.6195 mL | |
| 40 mM | 0.0786 mL | 0.3929 mL | 0.7858 mL | 1.9646 mL | |
| 50 mM | 0.0629 mL | 0.3143 mL | 0.6287 mL | 1.5717 mL | |
| 60 mM | 0.0524 mL | 0.2619 mL | 0.5239 mL | 1.3097 mL | |
| 80 mM | 0.0393 mL | 0.1965 mL | 0.3929 mL | 0.9823 mL | |
| 100 mM | 0.0314 mL | 0.1572 mL | 0.3143 mL | 0.7858 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Meclofenamic acid sodium Related Classifications
HY-B1320 Related Classifications
Powered by Bioz